bump pt higher lt growth
rais pt base upon rais
lt ep growth forecast
major surpris merck june analyst meet
walk away greater confid compani abil
outgrow drug industri next sever year
bump long-term estim pt cfo rob davi state revenu
potenti time frame meaning underappreci
rais long-term keytruda gardasil anim health revenu project
boost compound-annual-growth-rate revenue ep
rais keytruda gardasil
anim health boost ep
rais pt ep
unch exhibit
merck showcas legaci vision leadership team execut emphas
merck expect continu succeed premier research-
presid roger perlmutt chief medic offic roy bayn anim
presid richard deluca also share stage three mrl
team lead includ head discoveri scienc translat medicin dean
li head neurosci discoveri fiona marshal head infecti
keytruda target anti-tumor activ cancer type exhibit
roy bayn convey specif enthusiasm breast prostat
cancer opportun merck expect tripl keytruda number approv
cancer indic breast cancer encourag earli
result adjuv neoadjuv set prostat cancer keytruda
combin either lynparza parpi chemo xtandi exhibit
import asid competitor announc close june
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
highlight keytruda continu demonstr appear best-
in-class cover jeff hung disclos roch tecentriq
cobimetinib mek combo improv vs keytruda monotherapi
braf wild-typ melanoma roch cover mark purcel
roy bayn view adjuv market opportun larg addit
encourag merck said although mani observ highlight
adjuv earlier treatment post surgeri cannib exist metastat
sale management differ view see adjuv larg addit
major patient treat metastat set present
metastat diseas background io adjuv opportun pleas see
may global pharma report publish conjunct mark
leverag io leadershipboth identifi compel new oncolog
mechan also incorpor immuno-biolog discoveri effort
across therapeut area manag highlight sinc novel oncolog
candid develop need combin keytruda merck
competit lead assess new mechan separ merck embed
immuno-biolog across discoveri effort therapeut area exhibit
except china momentum appear set persist china presid
romanelli driven stand-out perform among multi-national compani
includ revenu growth past month merck well
posit capit signific futur opportun keytruda
gardasil look forward updat regard prospect initi
nrdl list keytruda
anim health set continu grow market anim health presid
deluca discuss busi histor track record includ new product
approv success emphas high convict merck anim health
continu grow market mid-sing digit annual growth
prospect deluca also expect merck companion anim deliv new
product compet zoeti dermatolog come year rais
anim health sale compound-annual-growth-rate
management bullish potenti transform hiv treatment
prevent nrtti uniqu pharmacolog enabl potenti long
durat therapi hiv treatment dose possibl includ daili
weekli hiv prevent possibl includ monthli oral plu
month implant look forward develop progress includ
combin molecul decis come year
merck see gefapix pipelin product larg market
potenti await ph valid gefapix phase chronic cough
could broad applic sensori disord includ endometrial-
relat pain sleep apnea need see whether ph chronic cough
efficaci clinic compel confirm dysgeusia bad tast
disappoint merck disclos new pipelin candid merck
reveal specif new drug candid manag discuss
pneumococc vaccin candid greater coverag knew
candid preclin test surpris us meant
vaccin adult offer greater coverag valent
ph merck disclos addit serotyp
exhibit keytruda broad activ cancer type
exhibit keytruda earli evid breast cancer on-going trial
pt base base case ep target multipl
premium peer averag believ justifi
given acceler growth prospect emerg pipelin prospect
bull case ep
bull case ep
keytruda surpris upsid merck execut compel
competitor part trial fail ep forecast due higher-
base case ep
base case ep
merck deliv keytruda gardasil sale slightli expect
plu encourag pipelin progress expect pipelin continu
deliv posit newsflow add new growth driver
bear case ep
bear case ep
keytruda gardasil disappoint drive ep forecast
competitor io trial show surprisingli strong result rel keytruda
overweight merck base upon
compel long-term growth prospect
see upsid lt consensu driven
oncolog franchis gardasil cancer
pipelin option diseas beyond
oncolog come focu
next year
keytruda sale trend trial
immuno-oncolog news flow
extern busi develop
us ex-u price develop
competitor dataset newsflow
risk achiev price
upsid risk financi upsid pipelin
surpris competitor shortfal
downsid risk financi shortfal key
china price risk litig regulatori
exhibit phase pipelin may
price
price
price
compani data morgan stanley research estim thomson reuter valuat methodolog risk associ price target
referenc research report pleas contact client support follow us/canada hong kong latin
altern may contact invest repres morgan stanley research broadway attent research manag new
exhibit trade histor mean
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
